Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Linagliptin (BI 1356) in Type 2 Diabetes
NCT02183350Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2005
- Primary completion
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with adverse events up to 28 days, Number of patients with abnormal findings in physical examination up to 28 days and 4 more. Started Apr 2005; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183350.